British pharmaceutical company Hikma Pharmaceuticals announced Thursday that it anticipates significantly reduced revenue growth and has pulled back its long-term financial projections while its chief executive prepares to step down from his executive chairman role to concentrate on company restructuring efforts.
The announcement reflects ongoing challenges facing the generic medication producer, which is grappling with shrinking profit margins and intensifying competition in the lucrative U.S. injectable drug market alongside other companies in the sector.
The pharmaceutical firm now projects group revenue will expand by just 2% to 4% in 2026, a notable decline from the 7% growth rate it recorded in 2025.
Hikma anticipates its core operating profit will fall between $720 million and $770 million, compared to the $741 million it reported for 2025.
The company also announced that its Bedford manufacturing facility is expected to reach full commercial production capacity by 2028.
